
Rif S. El-Mallakh, MD
Dr El-Mallakh is a professor in the department of psychiatry and behavioral sciences and director of the Mood Disorders Research Program at the University of Louisville School of Medicine in Louisville, Kentucky.
Dr El-Mallakh is a speaker for Idorsia, Indivior, Intracellular Therapies, Janssen, Lundbeck, Noven, Otsuka, Sunovion, and Teva.
Articles by Rif S. El-Mallakh, MD


This article explains the role of medications that have high affinity to block dopamine D4.

Mental health leads with 36% of all outpatient visits and 39% of all telehealth services. What effect does this have on psychiatric practice?

“Perhaps the most important thing in our lives is really our relationships with the people we care about.”

What is the first thing you share with your patient when you are about to prescribe a new medication?

How do you choose medications based on the biologic abnormalities that are known to occur in bipolar illness?

The aggregation of psychiatric diagnoses in individual psychiatric patients, ie, the presence of multiple disorders in one individual, is a curious and sometimes disturbing observation in psychiatry.

Treatment of anxiety can be a challenge, since the mainstay of treatment may adversely affect the course of bipolar disorder.

Major depression is at once simple and complex. At one level, the treatment of this disorder is straightforward. Yet, at a multitude of other levels, it is a complex condition for which available treatments remain suboptimal.
Latest Updated Articles
- Clinical Depression: Complexities of Diagnosis and Management
Published: September 15th 2007 | Updated:
- The Anxious Bipolar Patient
Published: September 6th 2011 | Updated:
- Shared Risk Factors in Multiple Psychiatric Disorders
Published: June 12th 2013 | Updated: